| Accession | Title | Series type(s) | Organism(s) | Samples | GDS | Supplementary | Contact | Release date |
|---|---|---|---|---|---|---|---|---|
 Filter
|
DCC
|
Jan 27, 2024
|
||||||
| GSE254054 |
Clinical and Biomarker Results from A Phase II Trial of Combined Cabozantinib and Durvalumab in Patients with Chemotherapy-refractory Colorectal Cancer (CRC): CAMILLA CRC Cohort
|
120 |
|
Ayah N. Al-Bzour | Jan 27, 2024 |
